

Unlocking Precancer Detection: Physiology to Screening Strategies



Precancer Detection Is Critical Because Survival Rates Are Higher When CRC Is Detected Early¹


5-year relative survival rates¹
United States, 2014-2020; All patients followed through 2021

91%

5-year survival rate if cancer is localized¹

13%

5-year survival rate if cancer has metastasized¹



Advanced Precancerous Lesions (APLs) Have the Potential to Become Malignant²

Risk of malignancy increases with more severe and higher-grade dysplasia (carcinoma *in situ*).²

3- to 4-fold increase in **risk for CRC** development in individuals with APLs³

Early detection and removal of APLs can interrupt CRC development and decrease CRC-related mortality.⁴

67% reduction in **CRC incidence** with polyp removal⁴

CRC Screening Strategies: Reported Sensitivity for Precancer Detection

1 person icon represents 10 people
True positive
False negative

Colonoscopy

Stool-based tests

The mt-sDNA test*

FIT

Liquid biopsy

Precancer Sensitivity



89-95%⁵
(n=2290)



43%⁶
(n=1962)



23%^{5,†}
(n=3372)⁷



13%^{8,9}
(n=1116)⁸ (n=N/A)⁹

High-Grade Dysplasia Sensitivity

N/A



74%⁶
(n=106)



48%^{6,‡}
(n=106)



23% (n=31)⁸
29% (n=N/A)⁹

Disclaimer: Performance data presented in this table were collected in separate studies and are not direct evidence comparing these different screening modalities.

**Knowledge of a positive mt-sDNA test during colonoscopy improved adenoma detection rate (ADR) by 18-26%.
After a positive stool-based test, patients should expect an overall ADR of ≥40%.^{10,11}**

Disclaimer: The Cologuard Plus test is intended to screen adults 45 and older at average risk for colorectal cancer. Rx only. This document is not for promotional use.

*The mt-sDNA test reported here is based on the Cologuard Plus test data.

†OC-Sensor.

‡Polymedco OC-Auto® Micro 80 iFOB Test; positivity cutoff: hemoglobin >100 ng/mL.¹²

ADR: adenoma detection rate; APL: advanced precancerous lesion; cfdNA: cell-free DNA; CRC: colorectal cancer;

FIT: fecal immunochemical test; mt-sDNA: multi-target stool DNA.

1. Siegel RL, et al. *CA Cancer J Clin.* 2025;75(1):10-45. 2. Shussman N, Wexner SD. *Gastroenterol Rep (Oxf).* 2014;2(1):1-15. 3. He X, et al.

Gastroenterol. 2020;158(4):852-861.e4. 4. Shaikat A, et al. *Gastroenterol.* 2021;160(4):1397-1399.e3. 5. Lin JS, et al. *JAMA.* 2021;325(19):

1978-1998. 6. Cologuard Plus Clinician Brochure. Exact Sciences Corporation. Madison, WI. 7. Lin JS, et al. *JAMA.* 2021;325(19)(suppl):S1-S65.

8. Guardant Shield Provider Brochure. Accessed February 3, 2025. <https://shieldcancerscreen.com/wp-content/uploads/LBL-000351-R1-Shield-Provider-Labeling.pdf>. 9. Freenome announces topline results for PREEMPT CRC to validate the first version of its blood-based test for the early detection of colorectal cancer. [Press Release]. Published April 2, 2024. Accessed February 3, 2025. <https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer>

10. Anderson JC, et al. *Cancer Prev Res.* 2022;15(7):455-464. 11. Butterly LF, et al. *Am J Gastroenterol.* 2024;119(11):2215-2223. 12. Imperiale TF, et al. *N Engl J Med.* 2024;390(11)(suppl 1):984-993.

Learn more about colorectal cancer, colorectal cancer screening, and the Cologuard Plus™ test at Exact Academy.

exactsciences.com/exactacademy



**EXACT
SCIENCES**

July 2025 / MED-CG-2500089 (v1.0)

Cologuard Plus and the Exact Sciences logo are trademarks of Exact Sciences Corporation. All other trademarks are properties of their respective owners.
© 2025 Exact Sciences Corporation. All rights reserved.

**EXACT
SCIENCES**

